Cost-Effectiveness Analysis of an Intranasal Influenza Vaccine for the Prevention of Influenza in Healthy Children
- 1 August 2001
- journal article
- clinical trial
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 108 (2), e24
- https://doi.org/10.1542/peds.108.2.e24
Abstract
Objective.: Intranasal influenza vaccine has proven clinical efficacy and may be better tolerated by young children and their families than an injectable vaccine. This study determined the potential cost-effectiveness (CE) of an intranasal influenza vaccine among healthy children.Methods.: We conducted a CE analysis of data collected between 1996 and 1998 during a prospective 2-year efficacy trial of intranasal influenza vaccine, supplemented with data from the literature. The CE analysis included both direct and indirect costs. We enrolled 1602 healthy children aged 15 to 71 months in year 1, 1358 of whom were enrolled in year 2. One or 2 doses of intranasal influenza vaccine or placebo were administered to measure the cost per febrile influenza-like illness (ILI) day avoided.Results.: During the 2-year study period, vaccinated children had an average of 1.2 fewer ILI fever days/child than unvaccinated children. In an individual-based vaccine delivery scenario with vaccine given twice in the first year and once each year thereafter at an assumed base case total cost of $20 for the vaccine and its administration (ie, per dose), CE was approximately $30/febrile ILI day avoided. CE ranged from $10 to $69/febrile ILI day avoided at $10 to $40/dose, respectively. In a group-based delivery scenario, vaccination was cost saving compared with placebo and remained so if vaccine cost was <$28 (the break-even price per dose). In the individual-based scenario, vaccination was cost saving if vaccine cost was <$5. In this scenario, nearly half of lost productivity in the vaccine group was attributable to vaccine visits, which overshadowed the relatively modest savings in ILI-associated costs averted.Conclusions.: Routine use of intranasal influenza vaccine among healthy children may be cost-effective and may be maximized by using group-based vaccination approaches. cost-effectiveness, influenza, vaccine, children.Keywords
This publication has 30 references indexed in Scilit:
- Influenza and the Rates of Hospitalization for Respiratory Disease among Infants and Young ChildrenNew England Journal of Medicine, 2000
- The Effect of Influenza on Hospitalizations, Outpatient Visits, and Courses of Antibiotics in ChildrenNew England Journal of Medicine, 2000
- Comparison of US Inactivated Split-Virus and Russian Live Attenuated, Cold-Adapted Trivalent Influenza Vaccines in Russian SchoolchildrenThe Journal of Infectious Diseases, 1996
- Cost Benefit of Combining AntigensBiologicals, 1994
- Review of Cost-Benefit Analyses of Influenza VaccinePharmacoEconomics, 1992
- Cost-benefit analysis of Haemophilus influenzae type b preventionThe Pediatric Infectious Disease Journal, 1990
- Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in FamiliesNew England Journal of Medicine, 1989
- Acute Respiratory Disease Associated with Influenza Epidemics in Houston, 1981-1983The Journal of Infectious Diseases, 1987
- Influenza: Its Control in Persons and PopulationsThe Journal of Infectious Diseases, 1986
- Longitudinal Studies of Types A and B Influenza among Seattle Schoolchildren and Families, 1968-1974The Journal of Infectious Diseases, 1976